Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ANGIODYNAMICS INC reported second quarter of fiscal year 2024 ended November 30, 2023 results: revenue $ 79.1 million, net income net loss of $ 29.0 million, EPS loss per share of $0.72.
- Period
- second quarter of fiscal year 2024 ended November 30, 2023
- Revenue
- $ 79.1 million
- Net income
- net loss of $ 29.0 million
- EPS
- loss per share of $0.72
- Result
- reported results
Exact text from the filing
Net sales for the second quarter of fiscal year 2024 were $ 79.1 million, an increase of 2.7% compared to the prior-year quarter. Foreign currency translation did not have a significant impact on the Company ' s net sales in the quarter. Med Tech net sales were $ 25.4 million, a 3.5 % increase from $24.5 million in the prior- year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform. Year-over-year growth was driven by Auryon sales during the quarter of $11.4 million, which increased 12.9%, and AlphaVac sales of $1.9 million, which grew 17.9%. AngioVac sales were $5.4 million in the quarter, a decline of 10.8% from the second quarter of fiscal 2023. The Company completed enrollment of its APEX-AV trial subsequent to quarter end. Med Device net sales were $ 53.7 million, a 2.3% increase from sales of $52.5 in the prior-year period. U.S. net sales in the second quarter of fiscal 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David D. Helsel resigned as Senior Vice President of Global Operations and R&D at ANGIODYNAMICS INC.
- Action
- resigned
- Role
- Senior Vice President of Global Operations and R&D
Exact text from the filing
On December 29, 2023, David D. Helsel, Senior Vice President of Global Operations and R&D, notified the Company of his intention to leave the Company, effective January 12, 2024, in order to pursue other opportunities.
View on SEC.gov